Publications by authors named "L Trapiella-Martinez"
Objectives: To assess the associations and prognostic value of scleroderma patterns by nailfold videocapillaroscopy (NVC) in patients with systemic sclerosis (SSc) and cutaneous subsets.
Methods: At baseline, 1356 SSc patients from the RESCLE registry were compared according to the scleroderma pattern as Late pattern and non-Late pattern, which included Early and Active patterns. Patient characteristics, disease features, survival time and causes of death were analysed.
Article Synopsis
- The study investigates left ventricular diastolic dysfunction (LVDD) in patients with Systemic Sclerosis (SSc) to understand its prevalence and the factors linked to it.
- Out of 1,517 SSc patients, 21% were found to have LVDD, with associations identified relating to older age, longer diagnosis time, presence of telangiectasia, and specific treatments.
- LVDD in SSc patients correlates with higher mortality rates and worse survival outcomes, though it wasn’t deemed an independent death risk factor.
Objectives: To assess the clinical profile of patients with anti-polymyositis/Scl (PM/Scl) antibodies in a cohort of Spanish patients with systemic sclerosis.
Methods: From the Spanish Scleroderma Study Group database, we selected patients in whom PM/Scl antibodies had been tested. We compared demographic, clinical, laboratory, and survival data between patients with and without PM/Scl antibodies.
Corrigendum to 'Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation' [AUTREV 19-5 (2020) 102507].
Autoimmun Rev
May 2021
The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i).
Rheumatology (Oxford)
February 2021
Introduction: Endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i) are beneficial in pulmonary arterial hypertension (PAH) and digital ulcers (DU) and prevent from DU recurrences. Our study aimed to determine the difference in the incidence rate of PAH and scleroderma renal crisis (SRC) in patients with SSc and DU (SSc-DU) under ERAs/PDE5i or without treatment.
Methods: We conducted a retrospective cohort study including SSc-DU patients from the Spanish Scleroderma Registry (RESCLE).